Efficacy and safety of licorice (Glycyrrhiza glabra) in moderately ill patients with COVID-19 : a randomized controlled trial
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
Licorice extract (glycyrrhizin), a potent antiviral, anti-inflammatory, and antioxidant remedy, is a potential therapeutic option for COVID-19. We evaluated the efficacy and safety of licorice in patients with moderate COVID-19. In this study, 60 patients with confirmed COVID-19 were randomly assigned in a 1:1 ratio to receive licorice (at a dose of 760 mg three times a day for seven days) or control groups. The primary outcomes were SPO2, body temperature, and respiratory rate (RR) after the end of the intervention. The findings indicated that SPO2, body temperature, and RR had no significant difference between the groups at the end of the intervention. However, CRP and ALT improved in the licorice group toward the baseline. The number of patients with worse prognoses, LOS, mortality, and the incidence of adverse events were not different between the groups at the end of the study. Licorice had no beneficial effect on the clinical symptoms of COVID-19. Moreover, this intervention demonstrated a safe profile of adverse events. The confirmation of the results of this preparatory trial requires more detailed multiple-center trials with a larger sample size.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 31(2023), 6 vom: 16. Dez., Seite 3037-3045 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ameri, Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
61ZBX54883 |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10787-023-01352-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363400346 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363400346 | ||
| 003 | DE-627 | ||
| 005 | 20240229163655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-023-01352-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1308.xml |
| 035 | |a (DE-627)NLM363400346 | ||
| 035 | |a (NLM)37847472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ameri, Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of licorice (Glycyrrhiza glabra) in moderately ill patients with COVID-19 |b a randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a Licorice extract (glycyrrhizin), a potent antiviral, anti-inflammatory, and antioxidant remedy, is a potential therapeutic option for COVID-19. We evaluated the efficacy and safety of licorice in patients with moderate COVID-19. In this study, 60 patients with confirmed COVID-19 were randomly assigned in a 1:1 ratio to receive licorice (at a dose of 760 mg three times a day for seven days) or control groups. The primary outcomes were SPO2, body temperature, and respiratory rate (RR) after the end of the intervention. The findings indicated that SPO2, body temperature, and RR had no significant difference between the groups at the end of the intervention. However, CRP and ALT improved in the licorice group toward the baseline. The number of patients with worse prognoses, LOS, mortality, and the incidence of adverse events were not different between the groups at the end of the study. Licorice had no beneficial effect on the clinical symptoms of COVID-19. Moreover, this intervention demonstrated a safe profile of adverse events. The confirmation of the results of this preparatory trial requires more detailed multiple-center trials with a larger sample size | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antioxidant | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cytokine storm | |
| 650 | 4 | |a Glycyrrhizin | |
| 650 | 4 | |a Licorice | |
| 650 | 7 | |a Glycyrrhiza glabra extract |2 NLM | |
| 650 | 7 | |a 61ZBX54883 |2 NLM | |
| 650 | 7 | |a Plant Extracts |2 NLM | |
| 700 | 1 | |a Farashahinejad, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Davoodian, Parivash |e verfasserin |4 aut | |
| 700 | 1 | |a Safa, Omid |e verfasserin |4 aut | |
| 700 | 1 | |a Kusha, Amin |e verfasserin |4 aut | |
| 700 | 1 | |a Dadvand, Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Hassanipour, Soheil |e verfasserin |4 aut | |
| 700 | 1 | |a Fathalipour, Mohammad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d 1996 |g 31(2023), 6 vom: 16. Dez., Seite 3037-3045 |w (DE-627)NLM090686616 |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:6 |g day:16 |g month:12 |g pages:3037-3045 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10787-023-01352-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 6 |b 16 |c 12 |h 3037-3045 | ||